HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshioka, T. Articles by Kanamaru, R. Search for Related Content PubMed PubMed Citation Articles by Yoshioka, T. Articles by Kanamaru, R.

Evaluation of ¹⁸F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer

¹ Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
² Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
³ Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
⁴ Department of Diagnostic Radiology, Tohoku University Hospital, Tohoku University, Sendai, Japan

PET with ¹⁸F-FDG has been widely used in oncology, but its application for stomach neoplasms has been limited. The aim of this study was to evaluate the visual diagnostic accuracy of ¹⁸F-FDG PET for advanced, metastatic, or recurrent gastric cancer and to generate semiquantitative values for lesions. Methods: ¹⁸F-FDG PET scans were obtained on 42 patients (29 men, 13 women; age, 27–78 y; median age, 63 y): 20 patients with a PT931/04 scanner and 22 patients with a SET2400W scanner. The PT931/04 has a spatial resolution of 6.0 mm at full width at half maximum (FWHM) and covers 15 cm above and below the targeted lesion, and the SET2400W has a spatial resolution of 3.9 mm at FWHM and images the entire body. All PET images were interpreted visually, and tracer uptakes were quantitated as standardized uptake values (SUVs) on SET2400W images. Results: The sensitivity, specificity, and accuracy as a whole were as follows: 71%, 74%, and 73%, respectively, with the SET2400W scanner and 47%, 79%, and 62%, respectively, with the PT931/04 scanner. Values were high for primary lesions, liver, lymph node, and lung metastases, but were low for bone metastases, ascites, peritonitis, and pleuritis carcinomatoses. SUVs were 8.9 ± 4.2 (primary lesions, 19 patients/19 lesions), 6.5 ± 2.2 (liver, 9/55), 6.1 ± 2.5 (lymph nodes, 14/38), 6.5 ± 1.8 (abdominal wall, 4/7), 3.9 ± 2.0 (bone, 3/27), and 4.7 ± 2.6 (lung, 2/3). Comparing SUVs and histologic findings for 17 untreated patients, values for well-differentiated and moderately differentiated adenocarcinomas versus poorly differentiated adenocarcinomas and signet ring cell carcinomas were 13.2 ± 6.3 (4/4) versus 7.7 ± 2.6 (13/13) (P < 0.05) for the primary lesions, 7.0 ± 2.4 (5/39) versus 5.6 ± 2.8 (2/2) for the liver, and 5.5 ± 1.9 (9/28) versus 8.8 ± 3.3 (3/8) (P < 0.05) for the lymph nodes. Conclusion: Our results indicate that ¹⁸F-FDG PET is a useful diagnostic modality for advanced, metastatic, or recurrent gastric cancer but not for detecting bone metastases, peritonitis, or pleuritis carcinomatoses. ¹⁸F-FDG uptake by gastric cancers is relatively high but does not parallel histopathologic features of malignancy.

Key Words: PET • ¹⁸F-FDG • gastric cancer

This article has been cited by other articles:

				Y. Nakamoto, K. Togashi, T. Kaneta, H. Fukuda, K. Nakajima, K. Kitajima, K. Murakami, H. Fujii, M. Satake, U. Tateishi, et al. Clinical Value of Whole-body FDG-PET for Recurrent Gastric Cancer: A Multicenter Study Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 297 - 302. [Abstract] [Full Text] [PDF]

				M. Zhang, X. Jiang, M. Zhang, H. Xu, G. Zhai, and B. Li The Role of 18F-FDG PET/CT in the Evaluation of Ascites of Undetermined Origin J. Nucl. Med., April 1, 2009; 50(4): 506 - 512. [Abstract] [Full Text] [PDF]

				K. Herrmann, K. Ott, A. K. Buck, F. Lordick, D. Wilhelm, M. Souvatzoglou, K. Becker, T. Schuster, H.-J. Wester, J. R. Siewert, et al. Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis J. Nucl. Med., December 1, 2007; 48(12): 1945 - 1950. [Abstract] [Full Text] [PDF]

				H. B. Prabhakar, D. V. Sahani, A. J. Fischman, P. R. Mueller, and M. A. Blake Bowel Hot Spots at PET-CT RadioGraphics, January 1, 2007; 27(1): 145 - 159. [Abstract] [Full Text] [PDF]

				J. S. Lim, M. J. Yun, M.-J. Kim, W. J. Hyung, M.-S. Park, J.-Y. Choi, T.-S. Kim, J. D. Lee, S. H. Noh, and K. W. Kim CT and PET in Stomach Cancer: Preoperative Staging and Monitoring of Response to Therapy RadioGraphics, January 1, 2006; 26(1): 143 - 156. [Abstract] [Full Text] [PDF]

				D. Utsunomiya, S. Shiraishi, M. Imuta, S. Tomiguchi, K. Kawanaka, S. Morishita, K. Awai, and Y. Yamashita Added Value of SPECT/CT Fusion in Assessing Suspected Bone Metastasis: Comparison with Scintigraphy Alone and Nonfused Scintigraphy and CT Radiology, December 1, 2005; 238(1): 264 - 271. [Abstract] [Full Text] [PDF]

				M. Yun, J. S. Lim, S. H. Noh, W. J. Hyung, J. H. Cheong, J. K. Bong, A. Cho, and J. D. Lee Lymph Node Staging of Gastric Cancer Using 18F-FDG PET: A Comparison Study with CT J. Nucl. Med., October 1, 2005; 46(10): 1582 - 1588. [Abstract] [Full Text] [PDF]

				M. Yun, H. S. Choi, E. Yoo, J. K. Bong, Y. H. Ryu, and J. D. Lee The Role of Gastric Distention in Differentiating Recurrent Tumor from Physiologic Uptake in the Remnant Stomach on 18F-FDG PET J. Nucl. Med., June 1, 2005; 46(6): 953 - 957. [Abstract] [Full Text] [PDF]

				M. C. A. van Kouwen, J. P. H. Drenth, W. J. G. Oyen, J. H. F. M. de Bruin, M. J. Ligtenberg, J. J. (H. Bonenkamp, J. H. J. M. van Krieken, and F. M. Nagengast [18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography Detects Gastric Carcinoma in an Early Stage in an Asymptomatic E-Cadherin Mutation Carrier Clin. Cancer Res., October 1, 2004; 10(19): 6456 - 6459. [Abstract] [Full Text] [PDF]